Physician profile

John W Mccarter

Internal Medicine · Norman, OK

NPI 1568445625

$2,246.76

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $321.80 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $271.47 2019-2020
Pfizer INC. $229.51 2019-2020
Lilly USA, LLC $229.13 2019-2020
Novo Nordisk INC $177.10 2019-2020
Amgen INC. $157.38 2019
Sanofi-Aventis U.S. LLC $122.84 2019-2020
Glaxosmithkline, LLC. $103.54 2019-2020
Janssen Pharmaceuticals, INC $101.57 2019-2020
Amarin Pharma, INC. $100.82 2019-2020
Abbvie INC. $97.30 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $73.86 2019-2020
Astellas Pharma US INC $70.04 2019-2020
Eisai INC. $57.68 2019-2020
Qol Medical, LLC $23.93 2019
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Regeneron Healthcare Solutions, INC. $18.63 2019
Genentech USA, INC. $14.85 2020
Ibsa Pharma INC. $14.78 2020
Medtronic USA, INC. $13.24 2019
Teva Pharmaceuticals USA, INC. $12.90 2019
Merck Sharp & Dohme LLC $12.78 2020
Kowa Pharmaceuticals America, INC. $11.36 2019
Bardy Diagnostics, INC. $10.25 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John W Mccarter

$2,246.76

in general payments reported 2019-2025

Years
2019-2022
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/161871/john-w-mccarter

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.